Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay
NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay   Study to Evaluate the Ability of PAM50 to Estimate Prognosis in Women with Early-Stage Breast Cancer SEATTLE, Wash. | May 16, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for
View HTML
Toggle Summary NanoString Technologies Names Joseph M. Beechem Senior Vice President of R&D
NanoString Technologies Names Joseph M. Beechem Senior Vice President of R&D   SEATTLE, Wash. | April 9, 2012   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of
View HTML
Toggle Summary Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies   Alexandria, VA | April 3, 2012   -  Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced a
View HTML
Toggle Summary NanoString Introduces Three New Products at AACR Annual Meeting
NanoString Introduces Three New Products at AACR Annual Meeting   New Offerings Accelerate the Completion of Studies and Expand FFPE Analysis Portfolio SEATTLE, Wash. | March 30, 2012   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Technologies Announces Positive Results from First Validation Study of PAM50-based Breast Cancer Assay
NanoString Technologies Announces Positive Results from First Validation Study of PAM50-based Breast Cancer Assay   Study Establishes Prognostic Performance of NanoString's First Diagnostic Product, Demonstrates NanoString's Assay Provides Significantly More Prognostic Information and
View HTML
Toggle Summary NanoString Secures $20M in Series D Financing
NanoString Secures $20M in Series D Financing   New Investors include GE healthymagination Fund, BioMed Ventures and Henri Termeer SEATTLE | November 7, 2011   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular
View HTML
Toggle Summary NanoString Announces Launch of Second Generation nCounter Analysis System
NanoString Announces Launch of Second Generation nCounter Analysis System   New Features Support Larger Translational Research Studies and Development of nCounter-based Diagnostics SEATTLE, Wash. and MONTREAL, Canada | October 12, 2011   -  NanoString Technologies, Inc., a privately held provider
View HTML
Toggle Summary NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels
NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels   Kit Enables Profiling of Up To 30 miRNAs and 200 mRNAs in a Single Tube without Amplification SEATTLE, Wash | September 21, 2011   -  NanoString Technologies, Inc., a privately held provider of life
View HTML
Toggle Summary NanoString Introduces Rat miRNA Expression Assays
NanoString Introduces Rat miRNA Expression Assays   Kit Enables Profiling of More than 400 Rat miRNAs in a Single Tube without Amplification SEATTLE, Wash | August 5, 2011   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of
View HTML
Toggle Summary NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay
NanoString Embarks on First in Series of Clinical Studies for Breast Cancer Intrinsic Subtyping Assay   Study to Evaluate Disease Prognosis Using NanoString? PAM50-based Assay on the TransATAC Sample Set SEATTLE, Wash | August 3, 2011   -  NanoString Technologies, Inc., a privately held provider of
View HTML